

Pneumococcal Vaccination Recommendations for Children and Adults by Age and/or Risk Factor¹

Routine Recommendations

for Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)

For children age 2 months and older
Administer PCV13 series to all children beginning at age 2 months, followed by doses at 4 months, 6 months, and 12–15 months (booster dose).

For adults age 65 years and older
Administer 1 dose of PPSV23 at age 65. However, if PCV13 is given at age 65 years based on shared clinical decision-making between the healthcare provider and the patient, delay PPSV23 until 1 year after PCV13.²

Risk-based Recommendations

People with Underlying Medical Conditions or Other Risk Factors

Risk Group	Underlying medical condition or other risk factor	PCV13			PPSV23	
		Administer PCV13 doses needed to complete series to children through age 71 months	Administer 1 dose to PCV13-naïve children age 6 through 18 years	Administer 1 dose to PCV13-naïve adults age 19 years and older	Administer 1 dose of PPSV23 at age 2 through 64 years	Administer a second dose of PPSV23 5 years after first dose if age younger than 65 years
Immuno-competent	Chronic heart disease ³	X			X	
	Chronic lung disease ⁴	X			X	
	Diabetes mellitus	X			X	
	Cerebrospinal fluid leak	X	X	X	X	
	Cochlear implant	X	X	X	X	
	Alcoholism, chronic liver disease, cirrhosis (6 yrs and older)				X	
	Cigarette smoking (19 yrs and older)				X	
Functional or anatomic asplenia	Sickle cell disease/other hemoglobinopathy	X	X	X	X	X
	Congenital or acquired asplenia	X	X	X	X	X
Immuno-compromised	Congenital or acquired immunodeficiency ⁵	X	X	X	X	X
	HIV	X	X	X	X	X
	Chronic renal failure	X	X	X	X	X
	Nephrotic syndrome	X	X	X	X	X
	Leukemia	X	X	X	X	X
	Lymphoma	X	X	X	X	X
	Hodgkin disease	X	X	X	X	X
	Generalized malignancy	X	X	X	X	X
	Iatrogenic immunosuppression ⁶	X	X	X	X	X
	Solid organ transplant	X	X	X	X	X
Multiple myeloma	X	X	X	X	X	

¹ Complete information on pneumococcal vaccine recommendations can be found at www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html

² PCV13 is no longer routinely recommended for adults age 65 years and older. However, PCV13 may be given at this age based on shared clinical decision-making between the provider and patient. See ACIP recommendations (www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm) for details.

³ Particularly cyanotic congenital heart disease and cardiac failure in children; including congestive heart failure and cardiomyopathy in all ages; excluding hypertension in adults.

⁴ Including asthma in children if treated with high-dose oral corticosteroid therapy, as well as chronic obstructive pulmonary disease (COPD), emphysema, and asthma in adults.

⁵ Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).

⁶ Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.